Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.40 |
| ▸ | JAK2 | O60674 | 9/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20851937 | 1.00 | JAK3 (0.40) | JAK3JAK2TNFPIM1PIM2 | |
| SCHEMBL20838977 | 1.00 | JAK3 (0.40) | JAK3JAK2TNFPIM1PIM2 | |
| SCHEMBL20838959 | 0.93 | JAK2 (0.38) | JAK3JAK2TNFMEN1KMT2A | |
| SCHEMBL23068547 | 0.90 | KMT2A (0.33) | JAK3JAK2MEN1KMT2AADORA3 | |
| SCHEMBL23068546 | 0.90 | KMT2A (0.33) | JAK3JAK2MEN1KMT2AADORA3 | |
| SCHEMBL21061357 | 0.90 | KMT2A (0.33) | JAK3JAK2MEN1KMT2AADORA3 | |
| SCHEMBL23084516 | 0.89 | JAK2 (0.42) | JAK3JAK2MEN1KMT2AMAPK3 | |
| SCHEMBL28472769 | 0.89 | JAK2 (0.42) | JAK3JAK2MEN1KMT2AMAPK3 | |
| SCHEMBL21098225 | 0.89 | JAK2 (0.42) | JAK3JAK2MEN1KMT2AMAPK3 | |
| SCHEMBL29489172 | 0.89 | JAK2 (0.42) | JAK3JAK2MEN1KMT2AMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684775-B1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| US-11866445-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2024-01-09 | — | — | US | disclosed |
| US-20220281889-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2022-09-08 | — | — | US | disclosed |
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-06-21 | — | — | US | disclosed |
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-06-21 | — | — | US | disclosed |
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2020-07-30 | — | — | US | disclosed |
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2020-07-30 | — | — | US | disclosed |
| EP-3684775-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2020-07-29 | — | — | EP | disclosed |
| CN-111108109-A | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019057806-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019057806-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281889-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE7A, PDE12 | JAK3 3205/4885JAK2 2666/4885TNF 969/4885 |
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE7A, PDE12 | JAK3 3205/4885JAK2 2666/4885TNF 969/4885 |
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE4A, PDE7A, PDE12 | JAK3 3205/4885JAK2 2666/4885TNF 969/4885 |
| US-11866445-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE4A, PDE7A, PDE12 | JAK3 3205/4885JAK2 2666/4885TNF 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.